Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Irene M. Ghobrial"'
Autor:
Lorenzo Trippa, Jacob P. Laubach, Paul G. Richardson, Elizabeth O'Donnell, Kathleen J. Lively, Robert L. Schlossman, Tianqi Chen, Irene M. Ghobrial, Andrew Yee, Philip M. Wade, Carol Ann Huff, Frank G. Basile, Nikhil C. Munshi, Jill N. Burke, Claudia E. Paba-Prada, Kenneth C. Anderson, Hannah Lyons, Cynthia C. Harrington, Noopur Raje
Publikováno v:
British Journal of Haematology. 182:222-230
We sought a regimen that incorporates optimal novel agents and balances efficacy with toxicity in transplant-ineligible multiple myeloma (MM) patients. Our study evaluated modified lenalidomide-bortezomib-dexamethasone (RVD lite) in this population a
Autor:
Juliette Bouyssou, Stephane Minvielle, Edie Weller, Aldo M. Roccaro, Jihye Park, Hervé Avet-Loiseau, Daisy Huynh, Karma Salem, Antonio Sacco, Federico Campigotto, Salomon Manier, Irene M. Ghobrial, Bradley Rivotto, Thierry Facon, Lorenzo Trippa, Philippe Moreau, Chia Jen Liu, Siobhan Glavey, Xavier Leleu, Jiantao Shi
Publikováno v:
Blood
Blood, American Society of Hematology, 2017, 129 (17), pp.2429-2436. ⟨10.1182/blood-2016-09-742296⟩
Blood, 2017, 129 (17), pp.2429-2436. ⟨10.1182/blood-2016-09-742296⟩
Blood, American Society of Hematology, 2017, 129 (17), pp.2429-2436. ⟨10.1182/blood-2016-09-742296⟩
Blood, 2017, 129 (17), pp.2429-2436. ⟨10.1182/blood-2016-09-742296⟩
International audience; Key Points • Two circulating exosomal microRNAs, let-7b and miR-18a, improved survival prediction in patients with MM. • Circulating exosomal miRNAs enhanced the stratification of patients with high-risk factors. Exosomes,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2eb4a4201c92ddd12cee18127823968a
https://www.hal.inserm.fr/inserm-01611113/file/ManierBlood2017Eq11.pdf
https://www.hal.inserm.fr/inserm-01611113/file/ManierBlood2017Eq11.pdf
Autor:
Sandra Kanan, Lian Xu, Christopher J. Patterson, Christina K. Tripsas, Irene M. Ghobrial, Jorge J. Castillo, Zachary R. Hunter, Patricia Sheehy, Barry Turnbull, Xia Liu, Kirsten Meid, Diane Warren, Stacey Chuma, Steven P. Treon, Guang Yang, Yang Cao
Publikováno v:
Blood. 124:503-510
Bortezomib frequently produces severe treatment-related peripheral neuropathy (PN) in Waldenström's macroglobulinemia (WM). Carfilzomib is a neuropathy-sparing proteasome inhibitor. We examined carfilzomib, rituximab, and dexamethasone (CaRD) in sym
Autor:
Dixil Francis, Amitabha Mazumder, Teru Hideshima, Irene M. Ghobrial, Nikhil C. Munshi, John Feather, Constantine S. Mitsiades, Dixie-Lee Esseltine, Laura E. Lunde, Wanling Xie, Robert Knight, Paul G. Richardson, Melissa Alsina, Sundar Jagannath, Jonathan L. Kaufman, Robert L. Schlossman, Kathleen Colson, Diane Warren, Andrzej Jakubowiak, Michelle E. Maglio, Kenneth C. Anderson, Edie Weller, Mary McKenney, Sagar Lonial, David H. Vesole, Noopur Raje
Publikováno v:
Blood. 123:1461-1469
In this prospective, multicenter, phase 2 study, 64 patients with relapsed or relapsed and refractory multiple myeloma (MM) received up to 8 21-day cycles of bortezomib 1.0 mg/m(2) (days 1, 4, 8, and 11), lenalidomide 15 mg/day (days 1-14), and dexam
Autor:
L. Gardner, Amrita Krishnan, Robert L. Schlossman, Jeff Allerton, Jacob P. Laubach, David Irwin, Sagar Lonial, Kathleen Colson, John J. Densmore, Noopur Raje, Peter Sportelli, Jeff Zonder, Enrique Poradosu, Jeff Wolf, Andrzej Jakubowiak, Kenneth C. Anderson, Michael Bar, Paul G. Richardson, Irene M. Ghobrial, Teru Hideshima, Thomas Martin, Nikhil C. Munshi
Publikováno v:
Journal of Clinical Oncology. 29:4243-4249
Purpose Novel agents have improved patient outcome in relapsed or relapsed/refractory multiple myeloma (MM). Preclinical data show that the novel signal transduction modulator, perifosine, enhances the cytotoxicity of dexamethasone and bortezomib. Cl
Autor:
Irene M. Ghobrial, William S. Dalton, Dixie-Lee Esseltine, Amitabha Mazumder, Melissa Alsina, David Avigan, Paul G. Richardson, Robert L. Schlossman, Teru Hideshima, Carol Delaney, Diane Warren, Nikhil C. Munshi, Deborah Doss, Kenneth C. Anderson, Sundar Jagannath, Laura E. Lunde, Rob Knight, Constantine S. Mitsiades, Edie Weller, Mary McKenney
Publikováno v:
Journal of Clinical Oncology. 27:5713-5719
Purpose Lenalidomide and bortezomib are active in relapsed and relapsed/refractory multiple myeloma (MM). In preclinical studies, lenalidomide sensitized MM cells to bortezomib and dexamethasone. This phase I, dose-escalation study (ie, NCT00153933)
Autor:
Houry, Leblebjian, Kimberly, Noonan, Claudia, Paba-Prada, Steven P, Treon, Jorge J, Castillo, Irene M, Ghobrial
Publikováno v:
American journal of hematology. 90(6)
Autor:
Nikhil C. Munshi, Robert J. Soiffer, Mary Doyle, Gary Bradwin, Irene M. Ghobrial, Constantine S. Mitsiades, Fangxin Hong, Edie Weller, Leslie Lockridge, Diane Warren, Brendan Connell, Paul G. Richardson, Kenneth C. Anderson, Deanna Tocco, Rachel P. Rosovsky, Robert L. Schlossman
Publikováno v:
British journal of haematology. 160(3)
In this prospective study of patients with relapsed or relapsed and refractory multiple myeloma (MM) treated with lenalidomide and dexamethasone, relationships between markers of endothelial stress and drug administration and incidence of venous thro
Autor:
A. Keith Stewart, Irene M. Ghobrial
Publikováno v:
Hematology. American Society of Hematology. Education Program.
A 51-year-old male was diagnosed with an IgA multiple myeloma (MM) after having back pain for several months. His bone marrow showed 30% involvement with plasma cells and his cytogenetics showed t(4:14). His β2-microglobulin was 6.5 mg/dL at diagnos
Autor:
Patricia Sheehy, Marybeth Nelson, Jacob D. Soumerai, Thomas J. Myers, Steven P. Treon, John Mattern, George P. Keogh, Dixie Lee Esseltine, Irene M. Ghobrial, Jeffrey Matous, Ann Birner, Leukothea Ioakimidis, Jakow G. Diener, Christopher J. Patterson, Andy Boral, Michael A. Willen
Purpose We examined the activity of bortezomib, dexamethasone, and rituximab (BDR) in patients with symptomatic, untreated Waldenström macroglobulinemia (WM). Patients and Methods A cycle of therapy consisted of bortezomib 1.3 mg/m2 intravenously; d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76854f2fd4c080ab67fe52bdd55279b8
https://europepmc.org/articles/PMC2727288/
https://europepmc.org/articles/PMC2727288/